Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “underperform” rating reissued by research analysts at Mizuho in a research note issued on Wednesday. They currently have a $8.00 price target on the specialty pharmaceutical company’s stock. Mizuho’s price objective suggests a potential downside of 43.14% from the stock’s previous close.

Other analysts have also recently issued reports about the stock. J P Morgan Chase & Co set a $10.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Monday, July 17th. BTIG Research restated a “neutral” rating on shares of Valeant Pharmaceuticals International in a research note on Wednesday, May 10th. BMO Capital Markets restated a “market perform” rating on shares of Valeant Pharmaceuticals International in a research note on Wednesday, May 10th. Guggenheim began coverage on shares of Valeant Pharmaceuticals International in a research note on Saturday, June 17th. They set a “buy” rating and a $18.00 price objective for the company. Finally, Wells Fargo & Company restated an “underperform” rating and set a $8.00 price objective (down from $11.50) on shares of Valeant Pharmaceuticals International in a research note on Sunday, April 23rd. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $17.26.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded down 10.04% on Wednesday, reaching $14.07. 39,170,357 shares of the company were exchanged. The stock’s market capitalization is $4.90 billion. The firm’s 50 day moving average price is $16.44 and its 200 day moving average price is $13.39. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $32.74.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. Valeant Pharmaceuticals International’s revenue was down 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.88) EPS. Equities research analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International’s (VRX) “Underperform” Rating Reaffirmed at Mizuho” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/valeant-pharmaceuticals-internationals-vrx-underperform-rating-reaffirmed-at-mizuho/1466604.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 20,000 shares of the company’s stock in a transaction dated Thursday, May 11th. The stock was acquired at an average price of $13.90 per share, with a total value of $278,000.00. Following the completion of the acquisition, the director now directly owns 70,572 shares of the company’s stock, valued at $980,950.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.87% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. Financial Architects Inc raised its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in Valeant Pharmaceuticals International by 4.5% in the first quarter. Janney Montgomery Scott LLC now owns 19,573 shares of the specialty pharmaceutical company’s stock worth $216,000 after buying an additional 848 shares during the last quarter. Korea Investment CORP acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth about $225,000. Sigma Planning Corp acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth about $184,000. Finally, Nationwide Fund Advisors raised its stake in Valeant Pharmaceuticals International by 3.8% in the first quarter. Nationwide Fund Advisors now owns 51,500 shares of the specialty pharmaceutical company’s stock worth $568,000 after buying an additional 1,900 shares during the last quarter. 51.14% of the stock is owned by institutional investors and hedge funds.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.